Today’s Research Reports on Trending Tickers: Conatus Pharmaceuticals and bluebird bio
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched a low of 23,523.16 before settling at 24,264.30, an increase of 0.96 percent, while the S&P 500 Index hit a low of 2,573.61 before rallying to close at 2,644.69, an increase of 1.16 percent. The tech-heavy Nasdaq Composite Index reached a low of 6,811.77 before settling to close at 7,042.11, an increase of 1.45 percent.
"The prospects for a trade war are there, investors are just not sure how to assess the impact that could come. This brings in an incredible amount of uncertainty, but people may just respond to things as they unfold," said Michael O'Rourke, chief market strategist at JonesTrading, according to MarketWatch.
RDI Initiates Coverage on:
Conatus Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=CNAT
bluebird bio, Inc.
https://rdinvesting.com/news/?ticker=BLUE
Conatus Pharmaceuticals stock moved 2.56% higher Wednesday, to close the day at $6.01. The stock recorded a trading volume of 837,054 shares, which was above its three months average volume of 609,583 shares. In the last year, Conatus Pharmaceuticals shares have traded in a range of 3.88 - 9.40. The share price has gained 54.90% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $5.99 is greater than its 200-day moving average of $5.11. Shares of Conatus Pharmaceuticals have fallen roughly 1.80 percent in the past month and are up 30.09 percent year-to-date.
Access RDI's Conatus Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CNAT
On Wednesday, shares of bluebird bio recorded a trading volume of 882,764 shares, which was below the three months average volume of 876,809 shares. The stock ended the day 7.88% higher at 173.10. The share price has gained 132.51% from its 52-week low with a 52-week trading range of 74.45 - 236.17. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $203.53 is greater than its 200-day moving average of $172.28. Shares of bluebird bio have fallen roughly 16.01 percent in the past month and are down 2.81 percent year-to-date.
Access RDI's bluebird bio, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=BLUE
Our Actionable Research on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) and bluebird bio, Inc. (NASDAQ:BLUE) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com